California -based Ambys has launched with $ $60m m in funding to develop treatments for serious liver diseases. The company raised $80m in a series A funding round led by Third Rock Ventures and Japan ’s Ambys , while another $80m was secured through a further partnership agreement with Takeda . The company is pursuing therapeutic modalities like cell therapy, hepatocyte transplantation and gene therapy for liver generation in patients with chronic liver diseases, as well as drug therapy to replace lost protein function. Third Rock Ventures will focus on the development of therapeutic modalities such as cell therapy, hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases.
California -based Ambys has launched with $ $60m m in funding to develop treatments for serious liver diseases. The company raised $80m in a series A funding round led by Third Rock Ventures and Japan ’s Ambys , while another $80m was secured through a further partnership agreement with Takeda . Third Rock Ventures will focus on the development of therapeutic modalities such as cell therapy, hepatocyte transplantation and gene therapy for the treatment of patients with chronic liver diseases.